Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07646873 · ClinicalTrials.gov registry record · NA
PET-Enabled Dual-Energy CT in Multiple Myeloma
A NA study, sponsored by University of California, Davis.
- Not yet
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT07646873: Clinical Trial NA study, sponsored by University of California, Davis.
NCT07646873 is a NA study that has not yet begun recruiting, run by University of California, Davis. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07646873, a NA study, has not yet begun recruiting, sponsored by University of California, Davis.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
This pilot study will evaluate a new imaging method called PET-enabled dual-energy CT for measuring bone and soft-tissue composition in bone marrow. The study will enroll adults with multiple myeloma who are scheduled to receive CAR T-cell therapy and healthy adult participants. All participants will undergo research imaging with dynamic 18F-FDG PET/CT and X-ray dual-energy CT. Participants with multiple myeloma will have imaging before CAR T-cell therapy and again after therapy. Healthy participants will have one imaging visit. The main goal is to compare bone and soft-tissue fraction measurements from PET-enabled dual-energy CT with measurements from standard X-ray dual-energy CT. The study will also explore whether corrected PET measurements are associated with bone marrow measurable residual disease, treatment response, and CAR T-cell therapy toxicities in participants with multiple myeloma. This study is not expected to provide direct medical benefit to participants. The information learned may help improve future PET/CT imaging methods for cancer evaluation.
Primary Outcome
Agreement between PET-enabled dual-energy CT and standard X-ray dual-energy CT will be assessed for quantitative bone fraction and soft-tissue fraction measurements in bone marrow regions.
Interventions
- DIAGNOSTIC_TEST PET-enabled dual-energy CT imaging
- DIAGNOSTIC_TEST X-ray dual-energy CT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-07 |
| Est. Completion | 2030-11 |
| Phase | NA |
What is known before NCT07646873 opens enrollment
NCT07646873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which PET-enabled dual-energy CT imaging is the first listed.
NCT07646873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07646873 about?
NCT07646873 is a clinical study titled "PET-Enabled Dual-Energy CT in Multiple Myeloma". This pilot study will evaluate a new imaging method called PET-enabled dual-energy CT for measuring bone and soft-tissue composition in bone marrow. The study will enroll adults with multiple myeloma who are scheduled to receive CAR T-cell therapy and healthy adult participants. All participants wi...
What is the current status of trial NCT07646873?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2026-07. Estimated completion is 2030-11.
What interventions are being tested in trial NCT07646873?
The interventions under investigation include: PET-enabled dual-energy CT imaging (DIAGNOSTIC_TEST), X-ray dual-energy CT imaging (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07646873?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07646873's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia